Mónica Garzón

TL;DR: It is shown that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.

TL;DR: A panel to use in ultra-deep sequencing to identify mutated alleles in cfDNA involved in non-small-cell lung cancer, gastrointestinal stromal tumour, colorectal carcinoma and melanoma and a feasible NGS panel for cfDNA analysis in clinical practice is developed.

TL;DR: Durvalumab treatment was feasible and safe in HIV-1-infected patients with cancer receiving combination antiretroviral therapy and patients on suppressive antifiltration therapy with advanced cancer should have access to cancer immunotherapy treatments.

TL;DR: The techniques available for the isolation and analysis of circulating free DNA and RNA, exosomes, tumor-educated platelets, and circulating tumor cells from the blood of cancer patients are summarized, and the clinical applications of liquid biopsy testing in lung cancer are discussed.

TL;DR: In this article, the authors presented a study sponsored by the Spanish Lung Cancer Group (SLCG) and supported by the AstraZeneca Group, which used a Marie Sklodowska-Curie Innovative Training Networks European Grant (ELBA No. 765492), the Spanish Association Against Cancer (AECC) (grant No.PROYE18012ROSE), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) supported in part the associated translational study.